3-cyclobutyl-8-(1-cyclobutylpiperidin-3-yl)-2,3,4,5-tetrahydro-1H-benzo[4,5]imidazo[1,2-d][1,4]diazepine | 1239878-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-cyclobutyl-8-(1-cyclobutylpiperidin-3-yl)-2,3,4,5-tetrahydro-1H-benzo[4,5]imidazo[1,2-d][1,4]diazepine
• 英文别名: 3-Cyclobutyl-8-(1-cyclobutylpiperidin-3-yl)-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazole
• CAS: 1239878-40-0
• 化学式: C₂₄H₃₄N₄
• 分子量: 378.561
• InChiKey: SQRVDIQAUVXFMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  24.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Chytil Milan

  公开号：US20100204214A1

  公开（公告）日：2010-08-12

  Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了融合咪唑基化合物，其合成方法以及使用方法。本文提供的化合物对于治疗、预防和/或管理各种疾病，如神经系统疾病和代谢性疾病，具有用处。本文提供的化合物抑制组胺H3受体的活性，并调节各种神经递质的释放，如组胺、乙酰胆碱、去甲肾上腺素和多巴胺（例如在突触处）。本文还提供了含有这些化合物的药物配方及其使用方法。
• US8063032B2
  申请人：——

  公开号：US8063032B2

  公开（公告）日：2011-11-22
• US8404670B2
  申请人：——

  公开号：US8404670B2

  公开（公告）日：2013-03-26
• [EN] HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF<br/>[FR] AGONISTES ET ANTAGONISTES INVERSES DE L'HISTAMINE H3 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SEPRACOR INC

  公开号：WO2010093425A1

  公开（公告）日：2010-08-19

  Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.